Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT07110454

Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

Led by Epiminder America, Inc. · Updated on 2026-05-06

210

Participants Needed

11

Research Sites

135 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use or are not able to use more standard monitoring techniques. This research is being done to understand how the Minder System helps physicians make decisions about participant's epilepsy treatment after an actionable event. The Minder System was granted De Novo classification by the U.S. Food and Drug Administration (FDA) and is not investigational. Participants that have completed the DETECT study and received the Minder System previously will consent to join this long-term follow-up observational study. The study will collect information about general wellbeing, use of healthcare services, and experience using the Minder data over time to support long-term epilepsy care. All participants will continue to be followed by their treating physician and undergo assessments and visits every six (6) months until two (2) years after receiving the Minder device.

CONDITIONS

Official Title

Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participant met all inclusion criteria, was enrolled in the DETECT study, and received the Minder device
  • Participant completed the DETECT study by receiving an actionable event or by completing the 6-month follow-up visit
  • Participant continues to have the Minder device implanted
  • Participant must continue to meet relevant DETECT study inclusion criteria
Not Eligible

You will not qualify if you...

  • Participant meets any relevant DETECT study exclusion criteria including needing treatments or assessments that are not indicated with the Minder System like Magnetic Resonance Imaging (MRI)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 11 locations

1

Mayo Clinic - Arizona

Phoenix, Arizona, United States, 85054

Actively Recruiting

2

Stanford

Palo Alto, California, United States, 94304

Actively Recruiting

3

Yale School of Medicine

New Haven, Connecticut, United States, 06510

Actively Recruiting

4

Mayo Clinic - Florida

Jacksonville, Florida, United States, 32224

Actively Recruiting

5

USF Health

Tampa, Florida, United States, 33606

Actively Recruiting

6

IU Health Neuroscience Center

Indianapolis, Indiana, United States, 46202

Enrolling by Invitation

7

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

Actively Recruiting

8

Mayo Clinic - Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

9

Washington University

St Louis, Missouri, United States, 63130

Actively Recruiting

10

Atrium Health Neurosciences Institute - Charlotte

Charlotte, North Carolina, United States, 28204

Actively Recruiting

11

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

E

Epiminder, Director of Clinical Trials

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here